A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Conditions:   Advanced Solid Tumor;   Head and Neck Squamous Cell Carcinoma;   Bladder Carcinoma;   Susceptible FGFR3 Genetic Alterations;   FGFR3;   FGFR3 Overexpression;   FGFR3 Receptor;   FGFR3 Protein Overexpression;   Ovarian Cancer;   Colorectal Cancer;   Breast Cancer;   Liver Cancer;   Lung Cancer;   Gastric Cancer
Interventions:   Drug: [225Ac]-FPI-1966;   Drug: [111In]-FPI-1967;   Biological: vofatamab
Sponsor:   Fusion Pharmaceuticals Inc.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 7, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine